Cantor Fitzgerald Reiterates Overweight on Invivyd, Maintains $10 Price Target
Cantor Fitzgerald analyst Josh Schimmer reiterates Invivyd (NASDAQ:IVVD) with a Overweight and maintains $10 price target.
Read original at benzingaStocks · News reference
The FDA Sent Invivyd An Advance Termination Notice For Pemgarda (Pemivibart) Emergency Use Authorization Following US Department Of Health And Human Services’ Announcement Of Advanced Notice Of Termination Of Covid-19 EUA Declaration On June 30, With Effective Date Of June 29, 2027
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jul 6, 2026, 11:11 AM
- Checked
- Jul 6, 2026, 11:15 AM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Invivyd Q2 EPS $(0.14) Misses $(0.11) Estimate, Sales $14.285M Miss $14.400M Estimate
Read original at benzinga8-K filing — Invivyd, Inc. (IVVD)
Filed: 2026-08-13 AccNo: 0001193125-26-349193 Size: 1 MB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read original at edgar